MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?
Key Points
CFO Setia Vishwas sold 36,371 common stock shares directly for a total transaction value of ~$1.02 million across three days in May 2026.
This represented 9.26% of Vishwas' direct holdings, reducing direct ownership to 356,256 shares post-sale.
No indirect or derivative trades occurred; the insider maintains only direct ownership in this class post-transaction.
Setia Vishwas, Chief Financial Officer of MapLight Therapeutics (NASDAQ:MPLT), reported the direct sale of 36,371 shares of Common Stock over multiple open-market transactions from May 4 to May 6, 2026, for a total consideration of approximately $1.02 million, according to the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 36,371 |
| Transaction value | $1.02 million |
| Post-transaction shares (direct) | 356,256 |
| Post-transaction value (direct ownership) | ~$10.35 million |
Transaction value based on SEC Form 4 weighted average purchase price ($28.17); post-transaction value based on May 6, 2026 market close ($29.04).
Key questions
- How does this sale compare to Vishwas' historical selling activity?
In the past year, Vishwas completed only two open-market sales, with this transaction representing the largest single disposition to date, but this reflects available share capacity rather than a shift in intent. - What was the impact on direct ownership and overall exposure?
The transaction reduced direct common stock holdings by 9.3%, and Vishwas continues to hold 356,256 shares directly after the sale. - Was this transaction part of a pre-arranged trading plan?
Yes, this transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Vishwas on Dec. 29, 2025. - Did the insider utilize any indirect entities or derivatives in this transaction?
No, the entire transaction involved direct holdings, with no shares traded via trusts or related entities and no derivative securities exercised or sold.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 5/6/26) | $29.04 |
| Market capitalization | $1.246 billion |
| Net income (TTM) | ($161.15 million) |
| Number of employees | 133 |
Company snapshot
- Key product candidates include ML-007C-MA for schizophrenia and Alzheimer's disease psychosis, ML-004 for autism spectrum disorder, ML-021 for Parkinson's disease motor deficits, and ML-009 for agitation-related disorders.
- The company operates a clinical-stage biopharmaceutical business model, focused on developing and advancing novel therapeutics targeting neural circuits implicated in central nervous system disorders.
MapLight Therapeutics is a clinical-stage biotechnology company specializing in the development of therapies for central nervous system (CNS) disorders. The company leverages proprietary neural circuit identification platforms to design targeted treatments for conditions such as schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, and Parkinson's disease. With a focused pipeline and an innovative approach to CNS therapeutics, MapLight aims to address significant unmet medical needs in the neurology and psychiatry markets.
What this transaction means for investors
It’s important to note that Vishwas’ recent share sale was pursuant to a a Rule 10b5-1 trading plan, a common tool insiders use to sell shares based on predetermined criteria like a specific date or price, and therefore shouldn’t be used as evidence of the CFO’s conviction in the company or knowledge about its future results.
Over the last year as of May 6, MapLight stock had gained an impressive 70.8%, most of which came in March 2026, after it released its fourth-quarter and full-year financial results. The company reported first-quarter 2026 results on May 14, which highlighted an expanded clinical pipeline in its core treatment areas of schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder, but that clinical work also came with rising operating expenses and deepening losses.
MapLight is a small-cap clinical-stage biopharmaceutical company that is currently unprofitable. Betting on this stock could prove lucrative if it can produce strong clinical trial results. But investors should brace for a bumpy ride and pay close attention to the data readouts that are due later this summer.
Should you buy stock in MapLight Therapeutics right now?
Before you buy stock in MapLight Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and MapLight Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $468,861!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,445,212!*
Now, it’s worth noting Stock Advisor’s total average return is 1,013% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of May 15, 2026.
Sarah Sidlow has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.